Emcure Pharmaceuticals Ltd (EMCURE) - Net Assets
Based on the latest financial reports, Emcure Pharmaceuticals Ltd (EMCURE) has net assets worth Rs49.77 Billion INR (≈ $538.21 Million USD) as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Rs96.12 Billion ≈ $1.04 Billion USD) and total liabilities (Rs46.36 Billion ≈ $501.35 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check EMCURE tangible net worth ratio to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | Rs49.77 Billion |
| % of Total Assets | 51.77% |
| Annual Growth Rate | 23.87% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 15.24 |
Emcure Pharmaceuticals Ltd - Net Assets Trend (2022–2026)
This chart illustrates how Emcure Pharmaceuticals Ltd's net assets have evolved over time, based on quarterly financial data. See EMCURE cash and liquid assets coverage to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for Emcure Pharmaceuticals Ltd (2022–2026)
The table below shows the annual net assets of Emcure Pharmaceuticals Ltd from 2022 to 2026. For live valuation and market cap data, see EMCURE market cap overview.
| Year | Net Assets | Change |
|---|---|---|
| 2026-03-31 | Rs49.77 Billion ≈ $538.21 Million |
+7.22% |
| 2025-03-31 | Rs46.42 Billion ≈ $501.97 Million |
+48.68% |
| 2024-03-31 | Rs31.22 Billion ≈ $337.61 Million |
+17.82% |
| 2023-03-31 | Rs26.50 Billion ≈ $286.55 Million |
+25.33% |
| 2022-03-31 | Rs21.14 Billion ≈ $228.64 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Emcure Pharmaceuticals Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 100.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (March 2026)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | Rs1.90 Billion | 3.83% |
| Other Components | Rs47.60 Billion | 96.17% |
| Total Equity | Rs49.50 Billion | 100.00% |
Emcure Pharmaceuticals Ltd Competitors by Market Cap
The table below lists competitors of Emcure Pharmaceuticals Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
F&G Annuities & Life Inc.
NYSE:FG
|
$3.64 Billion |
|
COPT Defense Properties
NYSE:CDP
|
$3.65 Billion |
|
Orla Mining Ltd
TO:OLA
|
$3.65 Billion |
|
Hisense Kelon Electrical Holdings Co Ltd
SHE:000921
|
$3.65 Billion |
|
Shenzhen Everbest Machinery Indus
SHE:002980
|
$3.64 Billion |
|
Appfolio Inc
NASDAQ:APPF
|
$3.64 Billion |
|
Zhengzhou Coal Mining Machinery Group Co Ltd
SHG:601717
|
$3.64 Billion |
|
LG Display Co. Ltd
F:LGA
|
$3.64 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Emcure Pharmaceuticals Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2025 to 2026, total equity changed from 44,461,860,000 to 49,500,320,000, a change of 5,038,460,000 (11.3%).
- Net income of 9,243,610,000 contributed positively to equity growth.
- Dividend payments of 568,530,000 reduced retained earnings.
- Other factors decreased equity by 3,636,620,000.
Equity Change Factors (2025 to 2026)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | Rs9.24 Billion | +18.67% |
| Dividends Paid | Rs568.53 Million | -1.15% |
| Other Changes | Rs-3.64 Billion | -7.35% |
| Total Change | Rs- | 11.33% |
Book Value vs Market Value Analysis
This analysis compares Emcure Pharmaceuticals Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 6.80x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 16.90x to 6.80x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2022-03-31 | Rs105.11 | Rs1776.00 | x |
| 2023-03-31 | Rs132.27 | Rs1776.00 | x |
| 2024-03-31 | Rs156.12 | Rs1776.00 | x |
| 2025-03-31 | Rs237.71 | Rs1776.00 | x |
| 2026-03-31 | Rs261.17 | Rs1776.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Emcure Pharmaceuticals Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 18.67%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 10.04%
- • Asset Turnover: 0.96x
- • Equity Multiplier: 1.94x
- Recent ROE (18.67%) is below the historical average (21.09%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2022 | 33.32% | 11.48% | 0.95x | 3.05x | Rs4.63 Billion |
| 2023 | 21.27% | 8.97% | 0.89x | 2.67x | Rs2.82 Billion |
| 2024 | 16.87% | 7.57% | 0.84x | 2.64x | Rs2.03 Billion |
| 2025 | 15.32% | 8.73% | 0.95x | 1.85x | Rs2.37 Billion |
| 2026 | 18.67% | 10.04% | 0.96x | 1.94x | Rs4.29 Billion |
Industry Comparison
This section compares Emcure Pharmaceuticals Ltd's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $18,853,775,461
- Average return on equity (ROE) among peers: 16.37%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Emcure Pharmaceuticals Ltd (EMCURE) | Rs49.77 Billion | 33.32% | 0.93x | $3.64 Billion |
| Aarey Drugs & Pharmaceuticals Limited (AAREYDRUGS) | $334.70 Million | 1.97% | 2.20x | $25.64 Million |
| Aarti Drugs Limited (AARTIDRUGS) | $1.23 Billion | 12.93% | 2.27x | $365.55 Million |
| Aarti Pharmalabs Limited (AARTIPHARM) | $19.90 Billion | 13.69% | 0.46x | $678.18 Million |
| Abbott India Limited (ABBOTINDIA) | $3.05 Billion | 19.95% | 0.50x | $6.02 Billion |
| Ajanta Pharma Limited (AJANTPHARM) | $2.98 Billion | 25.93% | 1.18x | $4.14 Billion |
| Akums Drugs and Pharmaceutical (AKUMS) | $7.20 Billion | -0.56% | 3.88x | $1.00 Billion |
| Alkem Laboratories Limited (ALKEM) | $63.09 Billion | 17.86% | 0.58x | $6.95 Billion |
| Amrutanjan Health Care Limited (AMRUTANJAN) | $1.09 Billion | 18.92% | 0.29x | $170.48 Million |
| Alembic Pharmaceuticals Limited (APLLTD) | $51.90 Billion | 11.24% | 0.50x | $1.62 Billion |
| Aurobindo Pharma Limited (AUROPHARMA) | $37.76 Billion | 41.73% | 1.51x | $9.32 Billion |
About Emcure Pharmaceuticals Ltd
Emcure Pharmaceuticals Limited provide quality and affordable healthcare solutions worldwide. It offers products in various therapeutic areas, such gynecology, anti-infectives, pain/analgesics, Vitamins, Minerals & Nutrients, blood-related, oncology, respiratory, HIV antivirals, gastro, anti-diabetic, neuro, and cardiovascular. It provides its products under Orofer XT, Tenectase, Pause, Metpure X… Read more